« Back to Directory of Resources
Treatments Under Development
Here you will find a list of current treatments under development:
| Brand Name: | |
| Generic Name: | |
| Code Name: | CX-4945 |
| Company: | Cylene |
| FDA Clinical Phase: | 1 |
Description:
CX-4945 is an oral anti-cancer agent. It inhibits CK2, an enzyme …
| Brand Name: | |
| Generic Name: | |
| Code Name: | CEP-18770 |
| Company: | Cephalon |
| FDA Clinical Phase: | 1/2 |
Description:
CEP-18770 is a boronic-acid based proteasome inhibitor that suppresses tumor growth by inhibiting the enzymes that break down important proteins in cancerous cells. Animal studies showed that …
| Brand Name: | |
| Generic Name: | |
| Code Name: | BI-505 |
| Company: | BioInvent |
| FDA Clinical Phase: | 1 |
Description:
BI-505 is a fully human antibody that causes cell death. It …
| Brand Name: | |
| Generic Name: | |
| Code Name: | BT-062 |
| Company: | Biotest |
| FDA Clinical Phase: | 1/2 |
Description:
BT-062 (news articles) …
| Brand Name: | ImMucin |
| Generic Name: | |
| Code Name: | |
| Company: | Vaxil BioTherapeutics |
| FDA Clinical Phase: | 1/2 |
Description:
ImMucin is a vaccine designed to stimulate the patient’s own …
| Brand Name: | |
| Generic Name: | |
| Code Name: | AT9283 |
| Company: | Astex |
| FDA Clinical Phase: | 2 |
Description:
AT9283 is a kinase inhibitor that prevents cell division, thereby stopping …